

Atty. Dkt. No. 041673-2069

Please amend the application as follows:

Amendments to the Claims:

This listing of claims *corrects* and *will replace* all prior versions, and listings, of claims in the application:

Listing of Claims:

87. (Currently Amended) A method for expressing a chimeric CD40 ligand in a CD40+ human cell, wherein the chimeric CD40 ligand includes one or more human domains derived from a human CD40 ligand gene and one or more murine mouse domains derived from a mouse CD40 ligand gene, the method comprising introducing a chimeric polynucleotide encoding the chimeric CD40 ligand into the cell.

88. (Previously Cancelled) The method of claim 87 wherein the non-human CD40 ligand comprises murine CD40 ligand.

89. (Previously Cancelled) A method for expressing a ligand capable of binding to a CD40 ligand receptor in a human cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or subdomain of human CD40 ligand and a domain or subdomain of non-human CD40 ligand into the cell.

90. (Previously Cancelled) A method for increasing the concentration of a ligand on the surface of a human cell, wherein the ligand is capable of binding to a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or sub-domain of human CD40 ligand a domain or subdomain of non-human CD40 ligand into the human cell, wherein the encoded CD40 ligand has increased stability on the surface of the cell relative to that of a human CD40 ligand.

92. (Previously Cancelled) The method of claim 89 or claim 90, wherein the non-human CD40 ligand domain or subdomain comprises a murine CD40 ligand domain or subdomain.

Atty. Dkt. No. 041673-2069

93. (Currently Amended) The method of claim 87 wherein the murine mouse domain comprises an extracellular CD40 ligand domain.

94. (Currently Amended) The method of claim 87 wherein the murine mouse CD40 ligand domain comprises Domain III of the mouse CD 40 ligand.

95. (Previously Presented) The method of claim 93 wherein the extracellular domain consists of Domain IV.

96. (Previously Cancelled) The method of claim 94 wherein the murine CD40 ligand further comprises Domain IV, or a subdomain of Domain IV, of the murine CD40 ligand.

97. (Currently Amended) The method of claim 87 wherein the murine mouse CD 40 ligand consists of Domain I of the murine mouse CD40 ligand.

98. (Currently Amended) The method of claim 87 wherein the murine mouse CD40 ligand consists of Domain II of the murine mouse CD40 ligand.

99. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 3.

100. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 20.

101. (Previously Cancelled) The method of claims 89 or 90, wherein the introduction of the nucleic acid sequence into the cell results in induced expression of surface markers on the cell.

102. (Previously Cancelled) The method of claim 101, wherein the surface markers comprise CD54, CD80, CD86, CD58, CD70 or CD95.

Atty. Dkt. No. 041673-2069

103. (Previously Cancelled) A method for expressing a ligand capable of binding to a CD40 ligand receptor in a human cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or subdomain of human CD40 ligand and a domain or subdomain of a non-human ligand selected from the group consisting of CD40 ligand, TNF alpha, TNF beta, CD70, CD30 ligand, 4-1 BBL, nerve growth factor and TNF-related apoptosis inducing ligand (TRAIL).

104. (Previously Cancelled) The method of claim 103 or claim 137, wherein the non-human ligand domain or subdomain comprises a murine ligand domain or subdomain.

105. (Previously Cancelled) The method of claim 104 wherein the murine ligand comprises Domain III, or a subdomain of Domain III, of the murine ligand.

106. (Previously Cancelled) The method of claim 104 wherein the murine ligand comprises Domain IV, or a subdomain of Domain IV, of the murine ligand.

107. (Previously Cancelled) The method of claim 105 wherein the murine ligand further comprises Domain IV, or a subdomain of Domain IV, of the murine ligand.

108. (Previously Cancelled) A method for expressing a ligand capable of binding to a CD40 ligand receptor in a human cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or subdomain of human CD40 ligand and a domain or subdomain of a human ligand selected from the group consisting of CD40 ligand, TNF alpha, TNF beta, CD70, CD30 ligand, 4-1 BBL, nerve growth factor and TNF related apoptosis inducing ligand (TRAIL).

109. (Previously Cancelled) The method of claim 108 or 138, wherein the human CD40 ligand comprises Domain IV, or a subdomain of Domain IV, of human CD40 ligand.

Atty. Dkt. No. 041673-2069

110. (Previously Cancelled) The method of claim 109 wherein the chimeric CD40 ligand comprises Domains I, II, and IV of human CD40 and Domain III of human CD70 receptor ligand.

111. (Previously Presented) The method of claim 87, wherein the human CD40+ cell comprises a neoplastic cell.

112. (Previously Cancelled) The method of claim 89 and 90 wherein the cell comprises a cell from connective tissue surrounding neoplastic cells.

113. (Previously Presented) The method of claim 111, wherein the neoplastic cell comprises a neoplastic B cell.

114. (Previously Cancelled) The method of claim 113, wherein the neoplastic B cell comprises a CLL cell.

115. (Previously Cancelled) The method of claim 113 wherein the neoplastic B cell is derived from a patient with a B cell malignancy.

116. (Previously Presented) The method of claim 111 wherein the neoplastic cell comprises a neoplastic T cell.

117. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a dendritic cell.

118. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a monocyte.

119. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a myelomonocyte.

120. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a cell derived from a breast tumor.

Atty. Dkt. No. 041673-2069

121. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a cell derived from an ovarian tumor.

122. (Previously Cancelled) The method of claim 111 wherein the neoplastic cell comprises a cell derived from a lung tumor.

123. (Previously Cancelled) A method for expressing a ligand capable of binding to a CD40 ligand receptor in a human neoplastic cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a chimeric CD40 ligand into the cell.

124. (Previously Cancelled) A method for increasing the concentration of a ligand on the surface of a human neoplastic cell, wherein the ligand is capable of binding to a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a chimeric CD40 ligand into the human cell, the chimeric CD40 ligand having increased stability on the surface of the cell relative to that of a human CD40 ligand.

125. (Previously Cancelled) The method of claims 123 and 124, wherein the neoplastic cell comprises a neoplastic B cell.

126. (Previously Cancelled) The method of claim 125, wherein the neoplastic B cell comprises a CLL cell.

127. (Previously Cancelled) The method of claim 125 wherein the neoplastic B cell is derived from a patient with a B cell malignancy.

128. (Previously Cancelled) The method of claims 123 and 124, wherein the neoplastic cell comprises a neoplastic T cell.

129. (Previously Cancelled) The method of claims 123 and 124 wherein the neoplastic cell comprises a dentritic cell.

Atty. Dkt. No. 041673-2069

130. (Previously Cancelled) The method of claims 123 and 124 wherein the neoplastic cell comprises a monocyte.

131. (Previously Cancelled) The method of claims 123 and 124 wherein the neoplastic cell comprises a myelomonocyte.

132. (Previously Cancelled) The method of claim 123 and 124 wherein the neoplastic cell comprises a cell derived from a breast tumor.

133. (Previously Cancelled) The method of claims 123 and 124 wherein the neoplastic cell comprises a cell derived from an ovarian tumor.

134. (Previously Cancelled) The method of claims 123 and 124 wherein the neoplastic cell comprises a cell derived from a lung tumor.

135. (Previously Cancelled) A method of expressing a ligand capable of binding to a CD40 ligand receptor in a human cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a chimeric CD40 ligand into the cell, wherein the cell is derived from connective tissue surrounding neoplastic cells.

136. (Previously Cancelled) A method for increasing the concentration of a ligand on the surface of a human cell derived from connective tissue surrounding neoplastic cells, wherein the ligand is capable of binding to a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a chimeric CD40 ligand into the human cell, the chimeric CD40 ligand having increased stability on the surface of the cell relative to that of a human CD40 ligand.

137. (Previously Cancelled) A method for increasing the concentration of a ligand on the surface of a human cell, wherein the ligand is capable of binding to a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or sub-domain of human CD40 ligand and a non-human ligand selected from the group consisting of CD40 ligand, TNF

Atty. Dkt. No. 041673-2069

alpha, TNF beta, CD70, CD30 ligand, 4-1 BBL, nerve growth factor and TNF related apoptosis inducing ligand (TRAIL).

138. (Previously Cancelled) A method for increasing the concentration of a ligand on the surface of a human cell, wherein the ligand is capable of binding to a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a domain or sub-domain of human CD40 ligand and a human ligand selected from the group consisting of CD40 ligand, TNF alpha, TNF beta, CD70, CD30 ligand, 4-1 BBL, nerve growth factor and TNF-related apoptosis inducing ligand (TRAIL).

139. (Previously Cancelled) The method of claims 89, 90, 103, 108, 137 or 138, wherein the cell comprises a human non-neoplastic cell that is CD40+.

140. (Previously Cancelled) The method of claim 139, wherein the cell comprises a B cell.

141. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 4.

142. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 5.

143. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 6.

144. (Previously Presented) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 7.